1-3 of 3
Kathleen Schwarz, MD
Close
Sort by
Journal Articles

Phase I/II Study of Myeloablative Anti-CD20+ Radioimmunotherapy with I-131-Rituximab in High-Risk CD20-Positive Non Hodgkin Lymphoma

Kathleen Schwarz, MD, Wagner Julia, MD, Susanne Schreiber, MD, Burkhard Schmidt, MD, Alexander Hoellein, MD, Mareike Verbeek, MD, Markus Schwaiger, MD, Christian Peschel, MD, Klemens Scheidhauer, MD, Christoph von Schilling, MD, Ulrich Keller, MD
Journal: Blood
Blood (2012) 120 (21): 3700.
https://doi.org/10.1182/blood.V120.21.3700.3700
Published: 2012
Journal Articles

Longitudinal Analysis of Serial Liver Biopsies in Chronically Transfused Sickle Cell Disease

Jaime L Wolfe, MD, Robert Anders, MD, PhD, Shirley Reddoch, MD, Kathleen Schwarz, MD, William Savage, MD
Journal: Blood
Blood (2011) 118 (21): 1052.
https://doi.org/10.1182/blood.V118.21.1052.1052
Published: 2011
Journal Articles

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relapsed Follicular, Indolent or Mantle-Cell Lymphoma: A Prospective “Dose”-Finding Study.

Christoph von Schilling, MD, Kathleen Schwarz, MD, Georg Hess, MD., Ph.D., Andreas Viardot, MD, Michael Sandherr, MD, Stefan Krause, MD., Ph.D., Jan P. Simon, MD, Ph.D., Nadine Roethling, Christian Peschel, MD, Ph.D., Markus Schwaiger, MD, Ph.D., Klemens Scheidhauer, MD, Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3426.
https://doi.org/10.1182/blood.V110.11.3426.3426
Published: 2007